ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξωμιξδ ΰϊ ψλιωϊ IVAX ξηζχϊ ΰϊ δξεαιμεϊ δβμεαμιϊ αβπψιχδ, ξεριτδ χεει ξεφψιν ηγωιν εωεεχιν φεξηιν26/1/2006 θας ξεγιςδ λι δωμιξδ ΰϊ ψλιωϊ (AMEX:IVX) IVAX. μηαψδ δξΰεηγϊ, ΰωψ ϊτςμ ϊηϊ δων ωμ θας. ϊδιδ πεληεϊ αμξςμδ ξ- 60 ξγιπεϊ εδιΰ ϊςριχ λ- 26,000 ςεαγιν. ωϊι δηαψεϊ ιιφψε δλπρεϊ ξςμ 7 ξιμιΰψγ γεμψ αωπιιν ςωψ δηεγωιν ωδρϊιιξε α 30 αρτθξαψ, 2005.
"ζδε ιεν ξψβω ςαεψπε", ΰξψ ιωψΰμ ξχεα, πωιΰ εξπλ"μ θας. "δωιμεα αιο θας μ- IVAX ιεφψ ηαψδ ιηεγιϊ, δηαψδ δβμεαμιϊ δξεαιμδ αϊςωιιϊ δϊψετεϊ δβπψιεϊ εηαψδ ςν τςιμεϊ ξωξςεϊιϊ αϊςωιιϊ δαψιΰεϊ δβμεαμιϊ. δψλιωδ ωμ Ivax ξηζχϊ ΰϊ δτςιμειεϊ εδξεαιμεϊ ωμπε δο αϊηεν δβπψι εδο αϊηεν διηεγι, ξςξιχδ ΰϊ φαψ δξεφψιν, ξψηιαδ ξωξςεϊιϊ ΰϊ τψιρϊιπε δβΰεβψτιϊ εξΰτωψϊ ΰϊ λπιρϊπε μϊηεξι θιτεμ ψτεΰιιν ηγωιν εαωεεχιν φεξηιν. ξδιεν θας ϊελμ μϊϊ ξςπδ θεα ςεγ ιεϊψ μφψλιδν ωμ χωϊ ψηαδ ωμ φψλπιν, μχεηεϊ ερτχι ωψεϊι αψιΰεϊ, δο ξαηιπδ θιτεμιϊ εδο ξαηιπδ λμλμιϊ."
Dr. Phillip Frost, ιε"ψ εξπλ"μ IVAX εξδιεν ρβο ιε"ψ γιψχθεψιεο θας ΰξψ, "ςαψε ξρτψ ηεγωιν ξΰζ ωδλψζπε ςμ δρλν ψλιωϊ IVAX ς"ι θας. αξδμκ ζξο ζδ ζλιπε μδλιψ ψαιν ξδξπδμιν δαλιψιν εΰπωι ξτϊη αθας. δϊψωξϊι ξδψξδ δβαεδδ ωμ ιλεμεϊιδν εξριψεϊν. διεν ιεϊψ ξϊξιγ ΰπι αθεη ω IVAX ξφΰδ ΰϊ δ-'αιϊ' δπλεο εϊπεδμ αλωψεο ψα ς"ι χαεφδ ιεφΰϊ γετο ζε - μϊεςμϊν ωμ δςεαγιν, δμχεηεϊ εαςμι δξπιεϊ λΰηγ."
ξψ ξχεα δερισ, "δϊημπε μτςεμ μξιξεω ϊλπιεϊιπε μΰιηεγ δςρχιν ωμ θας ε- IVAX, δτςμπε ϊδμιλι τιχεη εαχψδ ςμ ιιωεν ϊελπιεϊ ΰμε, ΰωψ ιαθιηε ξιχρεν δςψκ δτεθπφιΰμι ΰωψ θξεο αξιζεβ ωϊι δηαψεϊ δξεαιμεϊ αϊςωιιδ".
λτι ωλαψ δελψζ, θας φετδ λι δψλιωδ ϊϊηιμ μϊψεν μψεεη μξπιδ λαψ αξδμκ δωπδ δψΰωεπδ. θας ϊγεεη μψΰωεπδ ςμ πϊεπιν τιππριιν ξΰεηγιν μωϊι δηαψεϊ ςαεψ δψαςεο δψΰωεο ωμ 2006. αξεςγ τψρεν ζδ φτειδ δπδμϊ δηαψδ μϊϊ δλεεπδ μβαι δϊεφΰεϊ δφτειεϊ ωμ δηαψδ δξΰεηγϊ μωπϊ 2006.
α- 26 αιπεΰψ, 2006, IVAX δτλδ μηαψδ αϊ ααςμεϊ ξμΰδ ωμ θας εηγμδ ξμδρηψ ααεψρϊ δξπιεϊ δΰξψιχΰιϊ ((AMEX. αδξωκ μδρλν δψλιωδ ωπηϊν αιο δηαψεϊ, μαςμι ξπιεϊ IVAX διϊδ δζλεϊ μαηεψ αιο 0.8471 ξπιεϊ θας μαιο 26.00 γεμψ αξζεξο αϊξεψδ μλμ ξπιϊ IVAX ωααςμεϊν, αλτεσ μημεχδ ιηριϊ. αδϊαρρ ςμ ϊεφΰεϊ ξχγξιεϊ (ςγιιο μΰ ρετιεϊ) ωμ αηιψϊ αςμι δξπιεϊ εαλτεσ, αιο διϊψ, μΰιωεψ ϊεχτο ωμ αηιψεϊ ΰμε εηιωεαι δημεχδ διηριϊ δρετιϊ, ϊξεψϊ δξιζεβ ΰωψ ξεςψλϊ αξεςγ ζδ μϊωμεν μαςμι ξπιεϊ IVAX διπδ λγμχξο:
αηιψϊ ξπιεϊ: αςμι ξπιεϊ IVAX ΰωψ αιφςε αηιψδ ϊχτδ μχαμ ξπιεϊ αμαγ, φτειιν μχαμ 0.8471 ξπιεϊ θας μλ- 50.61% ξξπιεϊιδν α- IVAX ε- 26 γεμψ αξζεξο ςαεψ 49.39% ξξπιεϊιδν α- IVAX, ΰε ΰτχθιαιϊ μλμ ξπιδ: 0.4287 ξπιεϊ θας ε- 12.84 γεμψ μλμ ξπιϊ IVAX ωμβαιδ πςωϊδ αηιψδ ζε;
αηιψϊ ξζεξο: αςμι ξπιεϊ IVAX ΰωψ αιφςε αηιψδ ϊχτδ μχαμ ξζεξο αμαγ, ιχαμε 26.00 γεμψ αξζεξο ςαεψ λμ ξπιδ ωμ IVAX ωμβαιδ πςωϊδ αηιψδ ζε.
μμΰ αηιψδ: αςμι ξπιεϊ IVAX ΰωψ μΰ αιφςε αηιψδ ϊχτδ ιχαμε 26.00 γεμψ αξζεξο ςαεψ λμ ξπιδ ωμ IVAX.
δεγςδ μβαι δϊεφΰεϊ δρετιεϊ ωμ αηιψεϊ ΰμε φτειδ μδιπϊο αιεν ωμιωι δ- 31 αιπεΰψ, 2006 αχιψεα. αδξωκ μδρλν δξιζεβ, ημχι ξπιεϊ μΰ ιπϊπε εαξχεξο ιχαμε αςμι ξπιεϊ IVAX ξζεξο.
ξλϊα δεψΰεϊ μβαι δημτϊ δξπιεϊ εξλϊα δςαψδ ιωμηε αγεΰψ αχψεα μαςμι ξπιεϊ IVAX ΰωψ μΰ αηψε. αςμι ξπιεϊ IVAX ΰωψ αιφςε αηιψδ ϊχτδ αιο ξζεξο μξπιεϊ ΰιπν πγψωιν μπχεθ ατςεμδ περτϊ ςμ ξπϊ μχαμ ΰϊ ϊξεψϊ δξιζεβ.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ εαιιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ, διπδ ΰηϊ ξδξεαιμεϊ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο ΰξψιχδ εαΰιψετδ. χψεα μ- 90% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
ΰεγεϊ IVAX
IVAX Corporation, ωαριρδ αξιΰξι, τμεψιγδ, ξτϊηϊ ξιιφψϊ εξωεεχϊ ξεφψιν τψξφαθιιν ιιηεγιιν εβπψιιν ελο ξεφψιν εθψιπψιιν ετεςμϊ αΰψδ"α εαωΰψ δςεμν. ΰϊψ δηαψδ: www.ivax.com.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on managements current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva`s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate Ivax Corporation's operations and achieve expected synergies, Teva`s ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic products ,the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a resolution of outstanding litigation, including that relating to the generic versions of Allegra®, Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri® into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva`s ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism or major hostilities ,environmental risks, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |